Matthew Pauls, Director at Pelthos Therapeutics Inc. (PTHS), sold 786 shares at $20.52 ($16K) on 2026-04-02, disclosed to the SEC on 2026-04-06.
Scheduled sale ($16k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.52 | 415 | $9K | 51.8% |
| 2 | $21.36 | 371 | $8K | 48.2% |
| Total | $20.92 avg | 786 | $16K | 100% |
| Filing → |
| SVRA | SELL | 2024-12-16 | $362K | — | Filing → |
| SVRA | SELL | 2023-12-29 | $396K | — | Filing → |
| SVRA | BUY | 2021-12-08 | $7K | — | Filing → |